Total Results: 277
A selection of opinions on health care from around the country.
Media outlets report on news from Texas, Florida, Minnesota, California, Georgia, Massachusetts and Maryland.
Each week, KHN’s Shefali Luthra finds interesting reads from around the web.
A California lawmaker wants to strengthen collaboration among public agencies to bring down costs to taxpayers.
Doctors and drug developers have a stake in making cancer treatments seem better than they really are.
Read recent commentaries about drug-cost issues.
News outlets report on stories related to pharmaceutical pricing.
Shares for the pharmacy benefits manager dropped sharply following the announcement.
The drugmaker filed a lawsuit against the troubled EpiPen-maker on Monday. In other pharmaceutical news, The Daily Beast investigates the involvement of Rep. Chris Collins, R-N.Y., with an Australian biotech company, a panel of U.S. scientists is questioning the methodology of an Ebola drug trial, Biogen releases the promising results of a drug to help children with a neuromuscular disease, and one California lawmaker has a plan for lowering drug prices.
The consequences of the burnout can range from medical errors and high mortality rates of hospitalized patients to lower medical knowledge and impaired professionalism. In other public health news: cholesterol-lowering drugs, knee replacements, an ad campaign for condoms, the bird flu and more.
The drugmaker announced it was discontinuing its membership after it completed its sale of its Duchenne muscular dystrophy drug earlier that day. Meanwhile, the pharmaceutical industry’s lobbying spending has skyrocketed.
Even as drug pricing issues continue to draw scrutiny, federal safety regulations and incentives offer drug companies a new avenue to get a sweet return on their development costs.
With high drug prices creating widespread controversy, top pharmaceutical companies and their trade group vastly increased their lobbying spending on Capitol Hill.
Two companies that faced criticism for high-priced drugs, Marathon and Mallinckrodt, have dropped out of the PhRMA trade association.
“Today, we are facing another challenge, a plague that has been set upon the Cherokee people by these corporations,” said Todd Hembree, attorney general for the Cherokees. “Their main goal is profit, and this scourge has cost lives and the Cherokee Nation millions.”
Each week, KHN’s Shefali Luthra finds interesting reads from around the Web.
There’s no definitive guidance for doctors on what to do when their patient is someone who is in recovery from an opioid addiction, but also in need of pain relief. In other public health news: antidepressants, mysterious diseases, antibiotic-resistant infections, stress in kids and sexual enhancement pills.
The president often spoke about miners during his campaign, but as the deadline to renew benefits for them nears, he’s remained quiet.
The industries, which are often the focus of federal scrutiny, ponied up millions for the new president’s inauguration festivities.
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.